Events in our system are self-managed.  Group and event managers are encouraged to review privacy and security settings, and adjust them if needed.  If you need assistance please contact Indico Support - contact Help at bottom of page.

Apr 1 – 5, 2019
Fairmont Château Laurier Hotel
UTC timezone

In-vivo comparison of thorium-227 and zirconium-89 labeled 3,2-HOPO mesothelin antibody-chelator conjugate

Not scheduled
Fairmont Château Laurier Hotel

Fairmont Château Laurier Hotel


Dr Olav Benjamin Ryan (Bayer AS)


Targeted thorium conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for the targeted alpha therapy (TAT) of cancer. Cell surface glycoprotein mesothelin is highly expressed in many human cancers. Mesothelin targeted thorium-227 conjugate (MSLN-TTC, BAY 2287411), comprising a mesothelin targeted antibody (MSLN-Ab), covalently attached to 3,2-HOPO chelator, enabling specific complexation and delivery of the alpha particle emitter thorium-227 (227Th) to tumor cells, is currently in a phase 1 clinical trial (NCT03507452). 3,2-HOPO systems are also very efficient chelators for zirconium-89 and it has therefore been suggested that positron emission tomography (PET) imaging provides a useful surrogate for understanding 227Th radio-immunotherapy. Hence, we describe the radiolabeling of the conjugated MSLN-Ab conjugate with the PET isotope zirconium-89 (89Zr) and show data from a biodistribution study comparing both thorium and zirconium conjugates.
Email Address
Presentation Type Poster

Primary author

Dr Olav Benjamin Ryan (Bayer AS)


Dr Alan Cuthbertson (Bayer AS) Dr Alexander Kristian (Bayer AS) Dr Baard Indrevoll (Bayer AS) Dr Jenny Karlsson (Bayer AS) Dr Roger M Bjerke (Bayer AS) Dr Urs B Hagemann (Bayer AG)

Presentation materials

There are no materials yet.